secwatch.observer — SEC 8-K summary
======================================

Issuer:     vTv Therapeutics Inc. (VTVT)
CIK:        0001641489
Form:       8-K
Filed at:   2023-05-11T23:59:59+00:00
Accession:  0001641489-23-000019
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

vTv Therapeutics Q1 net loss narrows to $4.5M; cash rises to $18.8M; FDA agrees on pediatric study plan for TTP399
--------------------------------------------------------------------------------

- Net loss attributable to vTv shareholders was $4.5M ($0.06/share) vs $7.0M ($0.10/share) in Q1 2022.
- Cash and cash equivalents totaled $18.8M as of March 31, 2023, up from $12.1M at year-end 2022, after receiving $12M from G42 Investments.
- R&D expenses increased to $3.9M from $3.1M YoY, driven by TTP399 development costs; G&A expenses decreased to $3.5M from $5.3M.
- FDA agreed with pediatric study plan for TTP399 in type 1 diabetes patients aged 2-16; phase 2 study in type 2 diabetes on insulin therapy being prepared with G42 affiliate.
- Revenue was $0 in Q1 2023 vs $2M in Q1 2022 (prior collaboration revenue ended).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1641489/000164148923000019/0001641489-23-000019-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1641489/000164148923000019/vtvt-20230511.htm
  HTML page:      https://secwatch.observer/filing/0001641489-23-000019

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer